data_1jxd_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1jxd _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.647 0 N-CA-C 109.288 -0.634 . . . . 10.0 109.288 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -73.64 146.94 44.2 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 122.769 0.428 . . . . 10.0 110.818 -176.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.85 154.54 40.56 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.11 -1.071 . . . . 10.0 108.11 167.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 m -126.04 117.03 22.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.976 -1.12 . . . . 10.0 107.976 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 76.1 t -101.98 156.51 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 172.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.9 pttt -120.95 132.21 54.8 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.755 -0.59 . . . . 10.0 110.736 168.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 72.1 mtm -77.66 72.7 4.21 Favored 'General case' 0 C--N 1.34 0.179 0 C-N-CA 124.109 0.964 . . . . 10.0 109.159 177.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.97 149.17 9.01 Favored Glycine 0 N--CA 1.452 -0.287 0 N-CA-C 110.206 -1.158 . . . . 10.0 110.206 -178.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -61.93 140.86 58.28 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 108.989 -0.745 . . . . 10.0 108.989 171.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -74.71 69.61 1.8 Allowed 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 123.286 1.517 . . . . 10.0 107.667 167.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -169.99 -79.23 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 127.71 2.404 . . . . 10.0 107.276 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.93 47.97 0.03 OUTLIER Glycine 0 CA--C 1.527 0.826 0 C-N-CA 121.095 -0.574 . . . . 10.0 113.374 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -136.86 129.94 31.02 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.534 -0.913 . . . . 10.0 108.534 168.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -80.63 94.84 6.39 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-O 121.312 0.577 . . . . 10.0 109.815 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.6 m -131.11 139.4 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 125.553 1.541 . . . . 10.0 107.692 170.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -79.01 120.19 23.23 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 169.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -135.45 130.59 19.09 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-O 118.092 -0.956 . . . . 10.0 109.388 -178.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -64.29 137.13 27.2 Favored 'Cis proline' 0 N--CA 1.458 -0.582 0 CA-C-N 119.848 0.981 . . . . 10.0 110.872 -9.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.5 p -71.83 -17.53 62.14 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.642 1.177 . . . . 10.0 111.934 -177.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.1 m -143.29 127.43 17.54 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 107.813 -1.18 . . . . 10.0 107.813 173.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 m -123.25 146.93 27.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 C-N-CA 123.738 0.815 . . . . 10.0 108.859 179.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.6 m -127.17 116.33 20.46 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 107.019 -1.474 . . . . 10.0 107.019 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.2 pp -142.78 171.29 10.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 124.101 0.96 . . . . 10.0 108.637 -178.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -91.44 149.52 21.67 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 122.149 0.976 . . . . 10.0 113.116 -166.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -55.18 111.75 0.93 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 125.97 1.708 . . . . 10.0 110.358 174.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.27 -21.34 17.63 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 124.507 1.051 . . . . 10.0 111.527 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -77.23 178.47 7.05 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.157 0.979 . . . . 10.0 109.087 175.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -122.09 171.42 8.99 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.092 0.957 . . . . 10.0 110.603 178.19 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.6 t -138.37 136.43 44.18 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 N-CA-C 107.653 -1.239 . . . . 10.0 107.653 177.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.96 149.72 23.94 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.277 1.431 . . . . 10.0 109.329 177.036 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . . . . . . . . . 20.8 m-90 -119.32 143.44 47.37 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.987 1.315 . . . . 10.0 109.413 164.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 78.0 t -109.1 131.62 59.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.801 1.64 . . . . 10.0 109.321 175.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -77.53 145.15 37.11 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.45 0.7 . . . . 10.0 109.514 170.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.5 m-20 -132.27 -88.54 0.44 Allowed 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 123.121 0.568 . . . . 10.0 111.115 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -145.63 170.05 17.23 Favored 'General case' 0 N--CA 1.458 -0.057 0 C-N-CA 124.825 1.25 . . . . 10.0 108.416 -170.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 mt 64.25 33.94 11.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.487 1.115 . . . . 10.0 109.803 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -71.02 160.64 81.82 Favored Pre-proline 0 N--CA 1.448 -0.563 0 C-N-CA 124.755 1.222 . . . . 10.0 109.69 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -73.12 152.43 98.27 Favored 'Cis proline' 0 N--CA 1.454 -0.831 0 CA-C-N 118.855 0.627 . . . . 10.0 111.741 -2.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -126.34 159.4 33.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 156.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -130.66 169.61 15.41 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 160.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.5 mt -119.41 97.27 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 N-CA-C 105.009 -2.219 . . . . 10.0 105.009 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -113.37 111.74 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 -169.125 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.457 ' CD1' ' HB3' ' A' ' 79' ' ' TYR . 11.0 m-85 -83.0 120.33 25.58 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.342 -0.614 . . . . 10.0 109.342 -178.234 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -75.18 146.14 41.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 107.473 -1.306 . . . . 10.0 107.473 162.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.62 67.35 1.53 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.793 0.837 . . . . 10.0 108.989 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -86.52 66.8 9.67 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 121.77 0.795 . . . . 10.0 109.916 -159.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.32 -39.95 2.61 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.081 -1.207 . . . . 10.0 110.081 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.1 p -77.58 167.96 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 C-N-CA 123.158 0.583 . . . . 10.0 110.693 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.61 152.61 40.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.152 0.981 . . . . 10.0 111.205 -171.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.15 -54.7 43.83 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 115.316 -0.856 . . . . 10.0 111.265 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.38 -47.66 83.12 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.695 0.798 . . . . 10.0 111.154 -174.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . 0.254 14.9 t -62.86 -49.47 74.73 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 120.831 -0.348 . . . . 10.0 110.261 178.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -53.56 -41.48 66.55 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.729 -0.607 . . . . 10.0 111.62 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -62.74 -55.67 24.55 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.526 0.731 . . . . 10.0 109.865 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -61.72 -35.37 77.86 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.141 -0.349 . . . . 10.0 111.468 -176.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mp -72.4 -19.61 61.57 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 119.117 -0.468 . . . . 10.0 112.117 175.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.6 m -74.04 158.74 33.75 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.584 1.083 . . . . 10.0 111.433 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -132.87 98.56 4.34 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.335 1.854 . . . . 10.0 107.65 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -85.78 13.15 7.66 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 122.781 0.432 . . . . 10.0 111.163 166.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.76 129.26 24.44 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 109.527 -1.429 . . . . 10.0 109.527 173.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -78.57 119.68 22.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.229 0.612 . . . . 10.0 109.623 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -99.66 93.79 6.02 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 123.184 0.594 . . . . 10.0 111.423 -171.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -95.97 -42.44 8.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.878 -0.514 . . . . 10.0 110.354 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.71 127.09 31.84 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.987 0.422 . . . . 10.0 110.619 -173.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.45 80.54 0.39 Allowed 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.452 1.101 . . . . 10.0 108.107 169.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 162.69 -32.75 0.31 Allowed Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.263 -1.135 . . . . 10.0 110.263 -167.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 19.4 mm-40 -67.93 139.69 56.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 122.101 0.953 . . . . 10.0 108.436 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -143.83 149.28 36.74 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 13.6 m-30 -118.91 158.74 25.11 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 -174.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 93.3 m -137.32 140.93 41.83 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 123.715 0.806 . . . . 10.0 108.908 175.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.9 t -129.62 141.76 50.87 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.801 1.64 . . . . 10.0 107.589 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -99.49 113.45 25.84 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.967 1.307 . . . . 10.0 108.974 -175.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 6.5 m-30 -94.05 63.16 3.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.951 1.3 . . . . 10.0 108.09 -172.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.6 m -70.5 -63.21 1.14 Allowed 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 110.286 -0.264 . . . . 10.0 110.286 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -71.62 121.47 84.51 Favored Pre-proline 0 N--CA 1.453 -0.299 0 CA-C-O 117.768 -1.111 . . . . 10.0 109.435 -169.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -65.39 130.76 26.1 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.818 2.345 . . . . 10.0 108.637 176.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 159.66 179.21 34.32 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.559 -0.617 . . . . 10.0 111.559 -170.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 96.9 m -98.13 125.02 42.96 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.234 1.014 . . . . 10.0 109.332 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.457 ' HB3' ' CD1' ' A' ' 43' ' ' PHE . 69.4 m-85 -114.97 127.73 55.85 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 104.962 -2.236 . . . . 10.0 104.962 168.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.8 m -114.65 118.69 34.37 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.753 1.161 . . . . 10.0 108.919 176.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.403 ' HB3' ' CE1' ' A' ' 43' ' ' PHE . 4.0 p90 -109.73 146.07 35.53 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 123.767 0.827 . . . . 10.0 109.295 -173.308 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.37 -179.56 6.2 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.401 -0.963 . . . . 10.0 108.401 172.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 6.9 t -90.36 145.19 25.15 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 171.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -63.45 -58.89 13.52 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 119.79 1.177 . . . . 10.0 111.173 170.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.55 -51.73 3.86 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.939 1.371 . . . . 10.0 111.63 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -88.41 13.21 12.3 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.843 0.683 . . . . 10.0 112.843 -172.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 43.3 ttp180 -37.33 -58.28 0.84 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 127.083 2.153 . . . . 10.0 112.641 -176.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -101.61 13.91 57.9 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.895 0.759 . . . . 10.0 112.427 -174.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.22 11.92 21.84 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.385 1.092 . . . . 10.0 111.034 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 85.88 3.41 85.66 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-O 119.291 -0.727 . . . . 10.0 112.374 -176.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -90.04 97.96 11.5 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.676 1.238 . . . . 10.0 107.853 176.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 52.3 t -146.58 160.74 10.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.502 1.121 . . . . 10.0 108.135 176.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -146.32 165.54 28.23 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 109.262 -1.535 . . . . 10.0 109.262 172.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -133.46 150.93 51.73 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.425 1.09 . . . . 10.0 109.897 -172.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.0 t -129.2 135.0 62.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 106.91 -1.515 . . . . 10.0 106.91 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 67.2 t -119.5 99.57 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 O-C-N 124.93 1.394 . . . . 10.0 107.505 170.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.7 t -79.0 125.46 38.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 172.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--O 1.25 1.103 0 C-N-CA 125.625 1.57 . . . . 10.0 108.898 179.566 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.647 0 N-CA-C 109.288 -0.634 . . . . 10.0 109.288 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -73.64 146.94 44.2 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 122.769 0.428 . . . . 10.0 110.818 -176.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.85 154.54 40.56 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.11 -1.071 . . . . 10.0 108.11 167.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 m -126.04 117.03 22.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.976 -1.12 . . . . 10.0 107.976 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 76.1 t -101.98 156.51 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 172.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.9 pttt -120.95 132.21 54.8 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.755 -0.59 . . . . 10.0 110.736 168.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 72.1 mtm -77.66 72.7 4.21 Favored 'General case' 0 C--N 1.34 0.179 0 C-N-CA 124.109 0.964 . . . . 10.0 109.159 177.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.97 149.17 9.01 Favored Glycine 0 N--CA 1.452 -0.287 0 N-CA-C 110.206 -1.158 . . . . 10.0 110.206 -178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -61.93 140.86 58.28 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 108.989 -0.745 . . . . 10.0 108.989 171.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -74.71 69.61 1.8 Allowed 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 123.286 1.517 . . . . 10.0 107.667 167.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -169.99 -79.23 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 127.71 2.404 . . . . 10.0 107.276 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.93 47.97 0.03 OUTLIER Glycine 0 CA--C 1.527 0.826 0 C-N-CA 121.095 -0.574 . . . . 10.0 113.374 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -136.86 129.94 31.02 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.534 -0.913 . . . . 10.0 108.534 168.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -80.63 94.84 6.39 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-O 121.312 0.577 . . . . 10.0 109.815 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.6 m -131.11 139.4 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 125.553 1.541 . . . . 10.0 107.692 170.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -79.01 120.19 23.23 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 169.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -135.45 130.59 19.09 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-O 118.092 -0.956 . . . . 10.0 109.388 -178.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -64.29 137.13 27.2 Favored 'Cis proline' 0 N--CA 1.458 -0.582 0 CA-C-N 119.848 0.981 . . . . 10.0 110.872 -9.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.5 p -71.83 -17.53 62.14 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.642 1.177 . . . . 10.0 111.934 -177.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.1 m -143.29 127.43 17.54 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 107.813 -1.18 . . . . 10.0 107.813 173.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 m -123.25 146.93 27.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 C-N-CA 123.738 0.815 . . . . 10.0 108.859 179.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.6 m -127.17 116.33 20.46 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 107.019 -1.474 . . . . 10.0 107.019 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.545 HD11 ' CB ' ' A' ' 73' ' ' PHE . 2.2 pp -142.78 171.29 10.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 124.101 0.96 . . . . 10.0 108.637 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -91.44 149.52 21.67 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 122.149 0.976 . . . . 10.0 113.116 -166.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -55.18 111.75 0.93 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 125.97 1.708 . . . . 10.0 110.358 174.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.27 -21.34 17.63 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 124.507 1.051 . . . . 10.0 111.527 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -77.23 178.47 7.05 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.157 0.979 . . . . 10.0 109.087 175.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -122.09 171.42 8.99 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.092 0.957 . . . . 10.0 110.603 178.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.631 HG21 ' CE2' ' A' ' 73' ' ' PHE . 42.6 t -138.37 136.43 44.18 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 N-CA-C 107.653 -1.239 . . . . 10.0 107.653 177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.96 149.72 23.94 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.277 1.431 . . . . 10.0 109.329 177.036 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TRP . . . . . . . . . . . . . 20.8 m-90 -119.32 143.44 47.37 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.987 1.315 . . . . 10.0 109.413 164.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 78.0 t -109.1 131.62 59.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.801 1.64 . . . . 10.0 109.321 175.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -77.53 145.15 37.11 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.45 0.7 . . . . 10.0 109.514 170.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.5 m-20 -132.27 -88.54 0.44 Allowed 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 123.121 0.568 . . . . 10.0 111.115 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -145.63 170.05 17.23 Favored 'General case' 0 N--CA 1.458 -0.057 0 C-N-CA 124.825 1.25 . . . . 10.0 108.416 -170.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 mt 64.25 33.94 11.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.487 1.115 . . . . 10.0 109.803 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -71.02 160.64 81.82 Favored Pre-proline 0 N--CA 1.448 -0.563 0 C-N-CA 124.755 1.222 . . . . 10.0 109.69 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -73.12 152.43 98.27 Favored 'Cis proline' 0 N--CA 1.454 -0.831 0 CA-C-N 118.855 0.627 . . . . 10.0 111.741 -2.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -126.34 159.4 33.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 156.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -130.66 169.61 15.41 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 160.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.5 mt -119.41 97.27 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 N-CA-C 105.009 -2.219 . . . . 10.0 105.009 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -113.37 111.74 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 -169.125 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.501 ' CD1' ' HB3' ' A' ' 79' ' ' TYR . 11.0 m-85 -83.0 120.33 25.58 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.342 -0.614 . . . . 10.0 109.342 -178.234 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -75.18 146.14 41.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 107.473 -1.306 . . . . 10.0 107.473 162.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.62 67.35 1.53 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.793 0.837 . . . . 10.0 108.989 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -86.52 66.8 9.67 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 121.77 0.795 . . . . 10.0 109.916 -159.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.32 -39.95 2.61 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.081 -1.207 . . . . 10.0 110.081 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.411 HG11 ' CD2' ' A' ' 79' ' ' TYR . 2.1 p -77.58 167.96 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 C-N-CA 123.158 0.583 . . . . 10.0 110.693 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.61 152.61 40.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.152 0.981 . . . . 10.0 111.205 -171.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.15 -54.7 43.83 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 115.316 -0.856 . . . . 10.0 111.265 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.38 -47.66 83.12 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.695 0.798 . . . . 10.0 111.154 -174.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . 0.254 14.9 t -62.86 -49.47 74.73 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 120.831 -0.348 . . . . 10.0 110.261 178.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -53.56 -41.48 66.55 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.729 -0.607 . . . . 10.0 111.62 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -62.74 -55.67 24.55 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.526 0.731 . . . . 10.0 109.865 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -61.72 -35.37 77.86 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.141 -0.349 . . . . 10.0 111.468 -176.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mp -72.4 -19.61 61.57 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 119.117 -0.468 . . . . 10.0 112.117 175.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.6 m -74.04 158.74 33.75 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.584 1.083 . . . . 10.0 111.433 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -132.87 98.56 4.34 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.335 1.854 . . . . 10.0 107.65 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -85.78 13.15 7.66 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 122.781 0.432 . . . . 10.0 111.163 166.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.76 129.26 24.44 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 109.527 -1.429 . . . . 10.0 109.527 173.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -78.57 119.68 22.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.229 0.612 . . . . 10.0 109.623 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -99.66 93.79 6.02 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 123.184 0.594 . . . . 10.0 111.423 -171.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -95.97 -42.44 8.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.878 -0.514 . . . . 10.0 110.354 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.71 127.09 31.84 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.987 0.422 . . . . 10.0 110.619 -173.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.45 80.54 0.39 Allowed 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.452 1.101 . . . . 10.0 108.107 169.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 162.69 -32.75 0.31 Allowed Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.263 -1.135 . . . . 10.0 110.263 -167.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 19.4 mm-40 -67.93 139.69 56.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 122.101 0.953 . . . . 10.0 108.436 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -143.83 149.28 36.74 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 13.6 m-30 -118.91 158.74 25.11 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 -174.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 93.3 m -137.32 140.93 41.83 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 123.715 0.806 . . . . 10.0 108.908 175.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.9 t -129.62 141.76 50.87 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.801 1.64 . . . . 10.0 107.589 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -99.49 113.45 25.84 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.967 1.307 . . . . 10.0 108.974 -175.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CE2' HG21 ' A' ' 29' ' ' VAL . 6.5 m-30 -94.05 63.16 3.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.951 1.3 . . . . 10.0 108.09 -172.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.6 m -70.5 -63.21 1.14 Allowed 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 110.286 -0.264 . . . . 10.0 110.286 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -71.62 121.47 84.51 Favored Pre-proline 0 N--CA 1.453 -0.299 0 CA-C-O 117.768 -1.111 . . . . 10.0 109.435 -169.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -65.39 130.76 26.1 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.818 2.345 . . . . 10.0 108.637 176.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 159.66 179.21 34.32 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.559 -0.617 . . . . 10.0 111.559 -170.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 96.9 m -98.13 125.02 42.96 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.234 1.014 . . . . 10.0 109.332 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.501 ' HB3' ' CD1' ' A' ' 43' ' ' PHE . 69.4 m-85 -114.97 127.73 55.85 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 104.962 -2.236 . . . . 10.0 104.962 168.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.8 m -114.65 118.69 34.37 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.753 1.161 . . . . 10.0 108.919 176.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.462 ' HB3' ' CE1' ' A' ' 43' ' ' PHE . 4.0 p90 -109.73 146.07 35.53 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 123.767 0.827 . . . . 10.0 109.295 -173.308 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.37 -179.56 6.2 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.401 -0.963 . . . . 10.0 108.401 172.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 6.9 t -90.36 145.19 25.15 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 171.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -63.45 -58.89 13.52 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 119.79 1.177 . . . . 10.0 111.173 170.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.55 -51.73 3.86 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.939 1.371 . . . . 10.0 111.63 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -88.41 13.21 12.3 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.843 0.683 . . . . 10.0 112.843 -172.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 43.3 ttp180 -37.33 -58.28 0.84 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 127.083 2.153 . . . . 10.0 112.641 -176.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -101.61 13.91 57.9 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.895 0.759 . . . . 10.0 112.427 -174.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.22 11.92 21.84 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.385 1.092 . . . . 10.0 111.034 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 85.88 3.41 85.66 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-O 119.291 -0.727 . . . . 10.0 112.374 -176.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -90.04 97.96 11.5 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.676 1.238 . . . . 10.0 107.853 176.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 52.3 t -146.58 160.74 10.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.502 1.121 . . . . 10.0 108.135 176.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -146.32 165.54 28.23 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 109.262 -1.535 . . . . 10.0 109.262 172.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -133.46 150.93 51.73 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.425 1.09 . . . . 10.0 109.897 -172.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.0 t -129.2 135.0 62.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 106.91 -1.515 . . . . 10.0 106.91 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 67.2 t -119.5 99.57 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 O-C-N 124.93 1.394 . . . . 10.0 107.505 170.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.7 t -79.0 125.46 38.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 172.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--O 1.25 1.103 0 C-N-CA 125.625 1.57 . . . . 10.0 108.898 179.566 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 0.647 0 N-CA-C 109.288 -0.634 . . . . 10.0 109.288 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -73.64 146.94 44.2 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 122.769 0.428 . . . . 10.0 110.818 -176.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.85 154.54 40.56 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 108.11 -1.071 . . . . 10.0 108.11 167.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 52.8 m -126.04 117.03 22.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 107.976 -1.12 . . . . 10.0 107.976 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 76.1 t -101.98 156.51 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 N-CA-C 107.709 -1.219 . . . . 10.0 107.709 172.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.9 pttt -120.95 132.21 54.8 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.755 -0.59 . . . . 10.0 110.736 168.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' MET . . . . . . . . . . . . . 72.1 mtm -77.66 72.7 4.21 Favored 'General case' 0 C--N 1.34 0.179 0 C-N-CA 124.109 0.964 . . . . 10.0 109.159 177.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.97 149.17 9.01 Favored Glycine 0 N--CA 1.452 -0.287 0 N-CA-C 110.206 -1.158 . . . . 10.0 110.206 -178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -61.93 140.86 58.28 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 108.989 -0.745 . . . . 10.0 108.989 171.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -74.71 69.61 1.8 Allowed 'General case' 0 N--CA 1.451 -0.377 0 CA-C-O 123.286 1.517 . . . . 10.0 107.667 167.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 t -169.99 -79.23 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 127.71 2.404 . . . . 10.0 107.276 -179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 167.93 47.97 0.03 OUTLIER Glycine 0 CA--C 1.527 0.826 0 C-N-CA 121.095 -0.574 . . . . 10.0 113.374 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -136.86 129.94 31.02 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 108.534 -0.913 . . . . 10.0 108.534 168.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -80.63 94.84 6.39 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-O 121.312 0.577 . . . . 10.0 109.815 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.6 m -131.11 139.4 51.11 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 C-N-CA 125.553 1.541 . . . . 10.0 107.692 170.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -79.01 120.19 23.23 Favored 'General case' 0 N--CA 1.455 -0.181 0 N-CA-C 107.349 -1.352 . . . . 10.0 107.349 169.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -135.45 130.59 19.09 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-O 118.092 -0.956 . . . . 10.0 109.388 -178.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -64.29 137.13 27.2 Favored 'Cis proline' 0 N--CA 1.458 -0.582 0 CA-C-N 119.848 0.981 . . . . 10.0 110.872 -9.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.5 p -71.83 -17.53 62.14 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 124.642 1.177 . . . . 10.0 111.934 -177.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.1 m -143.29 127.43 17.54 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 107.813 -1.18 . . . . 10.0 107.813 173.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 16.2 m -123.25 146.93 27.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 C-N-CA 123.738 0.815 . . . . 10.0 108.859 179.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.6 m -127.17 116.33 20.46 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 107.019 -1.474 . . . . 10.0 107.019 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.545 HD11 ' CB ' ' A' ' 73' ' ' PHE . 2.2 pp -142.78 171.29 10.0 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 C-N-CA 124.101 0.96 . . . . 10.0 108.637 -178.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . 70.4 mttt -91.44 149.52 21.67 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 122.149 0.976 . . . . 10.0 113.116 -166.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -55.18 111.75 0.93 Allowed 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 125.97 1.708 . . . . 10.0 110.358 174.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.27 -21.34 17.63 Favored Glycine 0 CA--C 1.524 0.654 0 C-N-CA 124.507 1.051 . . . . 10.0 111.527 178.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -77.23 178.47 7.05 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 118.157 0.979 . . . . 10.0 109.087 175.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -122.09 171.42 8.99 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.092 0.957 . . . . 10.0 110.603 178.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.631 HG21 ' CE2' ' A' ' 73' ' ' PHE . 42.6 t -138.37 136.43 44.18 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 N-CA-C 107.653 -1.239 . . . . 10.0 107.653 177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.96 149.72 23.94 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.277 1.431 . . . . 10.0 109.329 177.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . . . . . . . . . 20.8 m-90 -119.32 143.44 47.37 Favored 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.987 1.315 . . . . 10.0 109.413 164.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 78.0 t -109.1 131.62 59.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.801 1.64 . . . . 10.0 109.321 175.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.5 t30 -77.53 145.15 37.11 Favored 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 123.45 0.7 . . . . 10.0 109.514 170.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.5 m-20 -132.27 -88.54 0.44 Allowed 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 123.121 0.568 . . . . 10.0 111.115 -177.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 36.4 mmtt -145.63 170.05 17.23 Favored 'General case' 0 N--CA 1.458 -0.057 0 C-N-CA 124.825 1.25 . . . . 10.0 108.416 -170.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 mt 64.25 33.94 11.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 124.487 1.115 . . . . 10.0 109.803 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.6 p -71.02 160.64 81.82 Favored Pre-proline 0 N--CA 1.448 -0.563 0 C-N-CA 124.755 1.222 . . . . 10.0 109.69 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -73.12 152.43 98.27 Favored 'Cis proline' 0 N--CA 1.454 -0.831 0 CA-C-N 118.855 0.627 . . . . 10.0 111.741 -2.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -126.34 159.4 33.3 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 106.039 -1.838 . . . . 10.0 106.039 156.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 4.4 p30 -130.66 169.61 15.41 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 106.955 -1.498 . . . . 10.0 106.955 160.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.5 mt -119.41 97.27 5.05 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 N-CA-C 105.009 -2.219 . . . . 10.0 105.009 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -113.37 111.74 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 N-CA-C 106.339 -1.726 . . . . 10.0 106.339 -169.125 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.501 ' CD1' ' HB3' ' A' ' 79' ' ' TYR . 11.0 m-85 -83.0 120.33 25.58 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.342 -0.614 . . . . 10.0 109.342 -178.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -75.18 146.14 41.51 Favored 'General case' 0 N--CA 1.446 -0.637 0 N-CA-C 107.473 -1.306 . . . . 10.0 107.473 162.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.62 67.35 1.53 Allowed 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 123.793 0.837 . . . . 10.0 108.989 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -86.52 66.8 9.67 Favored 'General case' 0 N--CA 1.456 -0.165 0 CA-C-O 121.77 0.795 . . . . 10.0 109.916 -159.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 103.32 -39.95 2.61 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.081 -1.207 . . . . 10.0 110.081 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.411 HG11 ' CD2' ' A' ' 79' ' ' TYR . 2.1 p -77.58 167.96 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 C-N-CA 123.158 0.583 . . . . 10.0 110.693 179.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.61 152.61 40.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.152 0.981 . . . . 10.0 111.205 -171.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.15 -54.7 43.83 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 115.316 -0.856 . . . . 10.0 111.265 -176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -58.38 -47.66 83.12 Favored 'General case' 0 N--CA 1.454 -0.252 0 C-N-CA 123.695 0.798 . . . . 10.0 111.154 -174.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . 0.254 14.9 t -62.86 -49.47 74.73 Favored 'General case' 0 N--CA 1.456 -0.172 0 C-N-CA 120.831 -0.348 . . . . 10.0 110.261 178.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -53.56 -41.48 66.55 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.729 -0.607 . . . . 10.0 111.62 177.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -62.74 -55.67 24.55 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 123.526 0.731 . . . . 10.0 109.865 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 11.5 tttt -61.72 -35.37 77.86 Favored 'General case' 0 CA--C 1.533 0.298 0 O-C-N 122.141 -0.349 . . . . 10.0 111.468 -176.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mp -72.4 -19.61 61.57 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-O 119.117 -0.468 . . . . 10.0 112.117 175.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 68.6 m -74.04 158.74 33.75 Favored 'General case' 0 C--N 1.339 0.132 0 CA-C-N 119.584 1.083 . . . . 10.0 111.433 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -132.87 98.56 4.34 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.335 1.854 . . . . 10.0 107.65 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -85.78 13.15 7.66 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 122.781 0.432 . . . . 10.0 111.163 166.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.76 129.26 24.44 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 109.527 -1.429 . . . . 10.0 109.527 173.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -78.57 119.68 22.19 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 123.229 0.612 . . . . 10.0 109.623 178.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -99.66 93.79 6.02 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 123.184 0.594 . . . . 10.0 111.423 -171.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -95.97 -42.44 8.28 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 121.878 -0.514 . . . . 10.0 110.354 -176.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.71 127.09 31.84 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-O 120.987 0.422 . . . . 10.0 110.619 -173.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.45 80.54 0.39 Allowed 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.452 1.101 . . . . 10.0 108.107 169.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 162.69 -32.75 0.31 Allowed Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.263 -1.135 . . . . 10.0 110.263 -167.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 19.4 mm-40 -67.93 139.69 56.44 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-O 122.101 0.953 . . . . 10.0 108.436 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 p -143.83 149.28 36.74 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 106.829 -1.545 . . . . 10.0 106.829 -179.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PHE . . . . . . . . . . . . . 13.6 m-30 -118.91 158.74 25.11 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 108.053 -1.091 . . . . 10.0 108.053 -174.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 93.3 m -137.32 140.93 41.83 Favored 'General case' 0 N--CA 1.455 -0.201 0 C-N-CA 123.715 0.806 . . . . 10.0 108.908 175.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 46.9 t -129.62 141.76 50.87 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 125.801 1.64 . . . . 10.0 107.589 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 1.1 m -99.49 113.45 25.84 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 124.967 1.307 . . . . 10.0 108.974 -175.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CE2' HG21 ' A' ' 29' ' ' VAL . 6.5 m-30 -94.05 63.16 3.15 Favored 'General case' 0 N--CA 1.453 -0.307 0 C-N-CA 124.951 1.3 . . . . 10.0 108.09 -172.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.6 m -70.5 -63.21 1.14 Allowed 'General case' 0 CA--C 1.529 0.14 0 N-CA-C 110.286 -0.264 . . . . 10.0 110.286 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -71.62 121.47 84.51 Favored Pre-proline 0 N--CA 1.453 -0.299 0 CA-C-O 117.768 -1.111 . . . . 10.0 109.435 -169.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -65.39 130.76 26.1 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.818 2.345 . . . . 10.0 108.637 176.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 159.66 179.21 34.32 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.559 -0.617 . . . . 10.0 111.559 -170.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 96.9 m -98.13 125.02 42.96 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 124.234 1.014 . . . . 10.0 109.332 178.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.501 ' HB3' ' CD1' ' A' ' 43' ' ' PHE . 69.4 m-85 -114.97 127.73 55.85 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 104.962 -2.236 . . . . 10.0 104.962 168.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 81.8 m -114.65 118.69 34.37 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.753 1.161 . . . . 10.0 108.919 176.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.462 ' HB3' ' CE1' ' A' ' 43' ' ' PHE . 4.0 p90 -109.73 146.07 35.53 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 123.767 0.827 . . . . 10.0 109.295 -173.308 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -141.37 -179.56 6.2 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 108.401 -0.963 . . . . 10.0 108.401 172.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' CYS . . . . . . . . . . . . . 6.9 t -90.36 145.19 25.15 Favored 'General case' 0 N--CA 1.443 -0.799 0 N-CA-C 107.222 -1.399 . . . . 10.0 107.222 171.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -63.45 -58.89 13.52 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 119.79 1.177 . . . . 10.0 111.173 170.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -61.55 -51.73 3.86 Favored 'Trans proline' 0 N--CA 1.455 -0.74 0 CA-C-N 120.939 1.371 . . . . 10.0 111.63 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -88.41 13.21 12.3 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.843 0.683 . . . . 10.0 112.843 -172.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ARG . . . . . . . . . . . . . 43.3 ttp180 -37.33 -58.28 0.84 Allowed 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 127.083 2.153 . . . . 10.0 112.641 -176.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -101.61 13.91 57.9 Favored Glycine 0 CA--C 1.527 0.813 0 C-N-CA 123.895 0.759 . . . . 10.0 112.427 -174.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -91.22 11.92 21.84 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 118.385 1.092 . . . . 10.0 111.034 178.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 85.88 3.41 85.66 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-O 119.291 -0.727 . . . . 10.0 112.374 -176.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -90.04 97.96 11.5 Favored 'General case' 0 CA--C 1.535 0.403 0 CA-C-N 118.676 1.238 . . . . 10.0 107.853 176.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 52.3 t -146.58 160.74 10.01 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.316 0 C-N-CA 124.502 1.121 . . . . 10.0 108.135 176.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -146.32 165.54 28.23 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 109.262 -1.535 . . . . 10.0 109.262 172.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -133.46 150.93 51.73 Favored 'General case' 0 CA--C 1.532 0.262 0 C-N-CA 124.425 1.09 . . . . 10.0 109.897 -172.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 3.0 t -129.2 135.0 62.92 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.519 0 N-CA-C 106.91 -1.515 . . . . 10.0 106.91 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 67.2 t -119.5 99.57 8.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 O-C-N 124.93 1.394 . . . . 10.0 107.505 170.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 35.7 t -79.0 125.46 38.4 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 N-CA-C 108.536 -0.913 . . . . 10.0 108.536 172.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--O 1.25 1.103 0 C-N-CA 125.625 1.57 . . . . 10.0 108.898 179.566 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_